Small-Cap Momentum Watch: June 29–July 2
6/28/20266 min read
This week’s small-cap watchlist highlights upcoming catalysts that could draw market attention, including operational updates, conference activity, and company-specific events. Keep in mind this is a shortened trading week: the NYSE and Nasdaq are closed Friday, July 3, 2026, for Independence Day observed, with an early close on Thursday, July 2.
--
Companies with Material Events This Week:
● PHIO – Management will participate in a Force Family Office fireside chat on June 29 at 12:00 PM ET, where CEO Robert Bitterman and Dr. James Cardia will discuss the company's INTASYL® siRNA platform and its approach to treating skin cancer. The company will also present at the Renmark Virtual Non-Deal Roadshow on June 30 at 12:00 PM ET, providing an overview of the INTASYL® platform, lead candidate PH-762, followed by a live investor Q&A.
● CMTL – Will showcase its newly available Allerium Mira cloud-native NG9-1-1 emergency communications platform at the NENA 2026 Conference & Expo, taking place June 29–30 in Columbus, Ohio. The platform supports next-generation emergency call handling, including voice, text-to-911, and future multi-channel communications.
● FBLG – CEO Pete O'Heeron will serve as a main stage speaker at the Alliance for Longevity Initiatives (A4LI) H-SPAN Summit, held June 29–July 1 at Georgetown University. The event brings together policymakers, scientists, and longevity leaders and concludes with a Congressional Briefing and Capitol Hill advocacy day.
● WKSP – Will host a live investor town hall on June 30 at 12:05 PM ET. Management will discuss recent business developments, execution priorities, and the company's strategy and growth plans for the second half of 2026.
● AUTL – Will participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference with a fireside chat on June 30 at 9:00 AM ET, where management is expected to provide updates on its next-generation CAR-T programs.
● TCRX – Will participate in a fireside chat at the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference on June 30 at 11:30 AM ET, highlighting progress across its TCR-engineered T-cell therapy pipeline.
● PSTV – Will host a business update conference call and webcast on June 30 at 8:30 AM ET. Management will discuss the commercial launch of CNSide®, development plans for lead therapeutic ReYobiq, its broader CNS oncology strategy, and AI initiatives.
● RC – Declared a $0.01 quarterly dividend, payable July 31, 2026, to shareholders of record June 30, 2026.
● VTGN – Expects topline Phase 3 PALISADE-4 data evaluating fasedienol for acute treatment of social anxiety disorder during June 2026, making this a key upcoming catalyst.
● LRE – Shareholders of record June 30, 2026 will be eligible for the company's planned annual cash dividend, with the final amount to be approved later this year.
● AFCG – Declared a $0.05 quarterly dividend, payable July 15, 2026, to shareholders of record June 30, 2026.
● RZLV – Shareholders will vote at the June 30 Annual General Meeting on proposals allowing the company to complete a capital reduction and authorize a share repurchase program of up to $300 million through BTIG. If approved and court-authorized, the company intends to begin repurchases using existing cash reserves.
● CHMI – Declared a $0.10 quarterly dividend, payable July 31, 2026, to shareholders of record June 30, 2026.
● LFT – Declared a $0.04 quarterly dividend, payable July 15, 2026, to shareholders of record June 30, 2026.
● XRX – Declared a $0.025 quarterly dividend, payable July 31, 2026, to shareholders of record June 30, 2026.
● BGS – Declared a $0.095 quarterly dividend, payable July 30, 2026, to shareholders of record June 30, 2026.
● AGEN – Will present three-year survival data from its Phase 1b study of botensilimab plus balstilimab in MSS metastatic colorectal cancer at the ESMO GI Congress in Munich. The poster presentation is scheduled for July 2, 2026, and includes updated durability of response and overall survival data.
● LFS – Expects to close its acquisition of Swift Japan on July 1, expanding its education and childcare ecosystem and extending customer engagement from infancy through youth sports.
● AIDX – Will launch a monthly investor webinar series beginning July 1 at 12:00 PM ET, providing recurring updates on corporate progress and business developments.
● GELS – Completed planning for its first human clinical trial, which is expected to begin during the third quarter starting July 1, advancing its pharmaceutical delivery platform toward a potential FDA regulatory pathway.
● GPMT – Declared a $0.05 quarterly dividend, payable July 15, 2026, to shareholders of record July 1, 2026.
● SXTP – Will meet with the FDA on July 1 regarding feedback on its New Dietary Ingredient Notification for Australian Chestnut Extract. The discussion will help determine additional safety information required before the company submits a revised application.
● PSEC – Expects to close the sale of Valley Electric to MYR Group around July 1 for approximately $328 million, generating an estimated 20.4% realized gross IRR and 4.8x multiple on invested capital over the life of the investment.
● SNAL – Continues executing its content roadmap, with ARK: Genesis Ascended Part 1 and ARK: Tides of Fortune currently scheduled for release July 2.
● LRMR – Will host an investor event on June 29 at 7:45 AM ET to discuss regulatory updates and new long-term clinical data from its nomlabofusp program for Friedreich's ataxia.
● FFAI – Recently unveiled the second half of its FF EAI Robot World ecosystem and introduced the Faber industrial mobile manipulator series. The company will debut Faber S at ISTE Live 26 on June 30, while continuing to expand its embodied AI robotics strategy.
● NKTX – Will participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference with a fireside chat on June 30 at 2:00 PM ET, highlighting progress in its CAR-NK cell therapy programs for autoimmune diseases.
● XTLB – A pivotal week as the company works toward completing its Psyga Bio acquisition by June 30, a key requirement for maintaining its Nasdaq listing. Shareholders will reconvene on June 29 to vote on the acquisition, related financing, and an increase in authorized share capital after the original meeting was adjourned for lack of quorum. Successful completion of the transaction is also tied to a $1.5 million private placement and Nasdaq's continued listing exception.
● TBH – The outside termination date for its proposed merger with House of Doge has been extended to June 30, 2026. If the transaction is not completed by then, either party may terminate the agreement.
● LHAI – Expects to close its acquisition of Mortgage One Group on or before July 1, combining a multi-state mortgage lending platform with the company's AI-powered real estate technology to create a more integrated home financing platform.
● IBO – Continues working toward its merger with Dr Ashleys Limited, with the agreement's termination date extended to July 1, 2026. The amended transaction includes revised share consideration, additional equity issuances, and financing arrangements, with completion dependent on remaining closing conditions and regulatory approvals.
--
Disclaimer: All content provided by BigTimePennys Report is for informational purposes only. The information provided should not be considered as a substitute for professional advice, analysis, or guidance. Any investment decisions made based on the information provided are solely at the user's own risk. BigTimePennys Report are not liable for any losses or damages incurred as a result of using this information. BigTimePenny is not operated by a licensed broker, a dealer, or a registered investment adviser. The Securities Litigation Reform Act of 1995 provides safe harbor protection for forward-looking statements made by companies or individuals. It should be noted that any forward-looking statements made by BigTimePennys Report, its authors, are not guarantees of future performance or results. These statements are subject to risks, uncertainties, and assumptions that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. The content provided by BigTimePennys Report does not constitute an endorsement, recommendation, or solicitation to buy, sell, or hold any securities or investment products. BigTimePennys Report, its authors, do not endorse or recommend any specific investment strategies, securities, or companies. It is crucial to conduct thorough research and seek advice from a qualified professional before making any investment decisions. Nothing in this article constitutes professional and/or financial advice, nor does any information in the article constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. The user assumes full responsibility for the use of the information provided by BigTimePennys Report. BigTimePennys Report, its authors, disclaim any liability for any direct, indirect, or consequential damages arising from the use or reliance on the information provided. Users should exercise their own judgment and discretion when interpreting and utilizing the information provided. Please note that the content provided by BigTimePennys Report is based on available information and sources believed to be reliable. However, market conditions and regulations may change over time, and there may be inaccuracies or errors in the information provided. It is recommended to verify the information with current and reliable sources before making any investment decisions. Investing in micro-cap companies is highly speculative and carries an extremely high degree of risk. BigTimePenny is not a fiduciary by virtue of any person's use of or access to this content. We were NOT compensated for this article.
Disclaimer: Penny stock trading involves substantial risk, so always research every alert before trading, consult with a licensed professional before trading, only invest what you can afford to lose, and always trade with caution. Readers should independently investigate and fully understand all risks before investing. Results listed are NOT typical and individual results may and most likely will vary. Bigtimepennystocks.com and its staff are NOT licensed investment advisors or broker/dealers of any kind.Alerts are not a solicitation or recommendation to buy/sell/hold securities but merely investment ideas that should NEVER serve as the basis of your trading decisions. Bigtimepennystocks.com and its newsletter are for entertainment purposes only. This website and its reports are for general information purposes as we are engaged in the business of marketing and advertising companies for monetary compensation. Any investment decision should be discussed with a financial adviser before taking place. Please invest carefully and read investment information available at the website of the SEC at http://www.sec.gov.
Subscribe to our Free Newsletter
Copyright © 2023 BigTimePennyStocks.com - All Rights Reserved.